Continuous Tableting Lines
At GEA we believe that continuous processing improves the quality of pharmaceutical end products: by focusing on quality during the whole product life-cycle, not just “tested in” quality; and by understanding the capability of your processes, managing sources of variability and decreasing any associated risks.
Our solution for continuous tableting lines is ConsiGma®, a 6 sigma-inspired manufacturing platform, incorporating different technologies to produce oral solid dosage forms in a continuous, cost-efficient way:
- by collecting more information during R&D phase, in a short time with less product
- by excluding risky, time- and product consuming scale-up exercises
- by introducing online measurement and closed loop control targeting real-time release (6 sigma production)
- by incorporating flexible batch size (JIT production), reducing inventory
- by reducing the energy cost per tablet, reducing environmental impact.
Products
Visualizzazione di 4 su 8
ConsiGma® Compact Feeder (CF) Test Rig
The ConsiGma® CF20 test rig is a standalone module that allows you to characterize the feeding behavior of your products during the early stages of R&D.
ConsiGma® Conductor
An indispensable part of the ConsiGma portfolio, the Conductor control system architecture ensures smooth operation and communication between the different elements of a pharmaceutical continuous manufacturing line
ConsiGma® Direct Compression with Linear Blending (DC-LB) Lines
A highly integrated solution for continuous linear blending and direct compression, the ConsiGma® DC-LB lines offer all the advantages of continuous manufacturing: supply chain agility, small footprint, controlled blending and compression and improved quality.
ConsiGma® Dosing and Blending (DB) Modules
Designed to achieve optimal blending results, the ConsiGma® DB modules facilitate the testing of dosing and blending operations and can be integrated with any continuous up- or downstream process.
Downloads
Approfondimenti GEA
GEA reports profitable growth for 2025 and expects accelerated revenue growth
GEA’s past fiscal year was one of significant growth and further profitability gains. In particular, the technology group substantially increased order intake, with all divisions contributing here. GEA also made progress in all Mission 30 strategic growth areas. In addition, GEA met key interim targets under its climate plan ahead of schedule. Major milestones in fiscal year 2025 were admission to the DAX index, the award of one of the largest contracts in the company’s history, and streamlining of the corporate structure.
Come SmartParc sta riscrivendo le regole della produzione alimentare
Grazie al nuovo sito produttivo SmartParc, le aziende di trasformazione alimentare del Regno Unito stanno riducendo i costi operativi e le emissioni. Basato sulla tecnologia di riscaldamento e raffreddamento GEA, questo modello di produzione collaborativo dimostra come l'innovazione stia accelerando le ambizioni di azzeramento delle emissioni nette del settore.
Il laboratorio di scienze alimentari
"Fare le uova come la birra". Un paragone che prima fa sorridere e poi riflettere: in effetti è il modo più semplice per spiegare qualcosa di molto complesso. Attraverso questo breve filmato girato nel cuore agricolo degli Stati Uniti, scopriamo la fermentazione di precisione e il lavoro concreto necessario per trasformare un'idea in cibo.
